Tikvah Management LLC (together with its affiliates, "Tikvah" or "we"), which owns approximately 1.5% of the outstanding common shares of Quanterix Corp. ("Quanterix" or the "Company") (Nasdaq: QTRX), ...

Kent Lake has previously issued a public presentation detailing its opposition to the Company's proposed transaction (the "Transaction") with Akoya and has also nominated three highly qualified, ...

Breast, pancreatic, and prostate cancers have a disproportionately higher rate of aggressive tumor grade in the target ...

Akoya Biosciences (AKYA) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.22 per share a year ago. These ...

Today, Kent Lake issued a statement related to recent disclosures indicating that Quanterix has officially entered into a Securities Purchase Agreement under which Akoya Biosciences (“Akoya ...

Akoya Biosciences (AKYA) and SAMBAI announced that Akoya’s PhenoCycler-Fusion system will be the foundational spatial proteomics technology ...

Quanterix sees growth with Akoya acquisition, but rising losses and investor skepticism persist. Explore challenges and ...

Akoya Biosciences, Inc. (NASDAQ:AKYA – Get Free Report) saw a large decline in short interest in March. As of March 15th, there was short interest totalling 2,490,000 shares, a decline of 30.8% from ...

Akoya, currently valued at $87.43 million, has seen its stock rise nearly 9% over the past week. The announcement aligns with concerns raised by other investors who have spoken against the deal ...